1
|
Richter JM, Gunaga P, Yadav N, Bora RO, Bhide R, Rajugowda N, Govindrajulu K, Godesi S, Akuthota N, Rao P, Sivaraman A, Panda M, Kaspady M, Gupta A, Mathur A, Levesque PC, Gulia J, Dokania M, Ramarao M, Kole P, Chacko S, Lentz KA, Sivaprasad Lvj S, Thatipamula RP, Sridhar S, Kamble S, Govindrajan A, Soleman SI, Gordon DA, Wexler RR, Priestley ES. Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart Failure. J Med Chem 2024; 67:9731-9744. [PMID: 38807539 DOI: 10.1021/acs.jmedchem.4c00893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2024]
Abstract
Recent literature reports highlight the importance of the renal outer medullary potassium (ROMK) channel in renal sodium and potassium homeostasis and emphasize the potential impact that ROMK inhibitors could have as a novel mechanism diuretic in heart failure patients. A series of piperazine-based ROMK inhibitors were designed and optimized to achieve excellent ROMK potency, hERG selectivity, and ADME properties, which led to the identification of compound 28 (BMS-986308). BMS-986308 demonstrated efficacy in the volume-loaded rat diuresis model as well as promising in vitro and in vivo profiles and was therefore advanced to clinical development.
Collapse
Affiliation(s)
- Jeremy M Richter
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| | - Prashantha Gunaga
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Navnath Yadav
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Rajesh Onkardas Bora
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Rajeev Bhide
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| | - Nagendra Rajugowda
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Kavitha Govindrajulu
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Sreenivasulu Godesi
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Nagarjuna Akuthota
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Prasanna Rao
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Aneesh Sivaraman
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Manoranjan Panda
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| | - Mahammed Kaspady
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Anuradha Gupta
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| | - Arvind Mathur
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| | - Paul C Levesque
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| | - Jyoti Gulia
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Manoj Dokania
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Manjunath Ramarao
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| | - Prashant Kole
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Silvi Chacko
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| | - Kimberley A Lentz
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| | - Sankara Sivaprasad Lvj
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | | | - Srikanth Sridhar
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Shyam Kamble
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Arun Govindrajan
- Biocon Bristol Myers Squibb Research Center, Syngene International Limited, Bangalore 560099, India
| | - Sharif I Soleman
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| | - David A Gordon
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| | - Ruth R Wexler
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| | - E Scott Priestley
- Bristol Myers Squibb Research & Early Development, Princeton, New Jersey 08540, United States
| |
Collapse
|
3
|
Jiang J, Ding FX, Zhou X, Bateman TJ, Dong S, Gu X, Keh deJesus R, Pio B, Tang H, Chobanian HR, Levorse D, Hu M, Thomas-Fowlkes B, Margulis M, Koehler M, Weinglass A, Gibson J, Houle K, Yudkovitz J, Hampton C, Pai LY, Samuel K, Cutarelli T, Sullivan K, Parmee ER, Davies I, Pasternak A. Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic. J Med Chem 2021; 64:7691-7701. [PMID: 34038119 DOI: 10.1021/acs.jmedchem.1c00406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A renal outer medullary potassium channel (ROMK, Kir1.1) is a putative drug target for a novel class of diuretics with potential for treating hypertension and heart failure. Our first disclosed clinical ROMK compound, 2 (MK-7145), demonstrated robust diuresis, natriuresis, and blood pressure lowering in preclinical models, with reduced urinary potassium excretion compared to the standard of care diuretics. However, 2 projected to a short human half-life (∼5 h) that could necessitate more frequent than once a day dosing. In addition, a short half-life would confer a high peak-to-trough ratio which could evoke an excessive peak diuretic effect, a common liability associated with loop diuretics such as furosemide. This report describes the discovery of a new ROMK inhibitor 22e (MK-8153), with a longer projected human half-life (∼14 h), which should lead to a reduced peak-to-trough ratio, potentially extrapolating to more extended and better tolerated diuretic effects.
Collapse
Affiliation(s)
- Jinlong Jiang
- Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Fa-Xiang Ding
- Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Xiaoyan Zhou
- Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Thomas J Bateman
- Pharmacokinetics Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Shuzhi Dong
- Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Xin Gu
- Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Reynalda Keh deJesus
- Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Barbara Pio
- Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Haifeng Tang
- Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Harry R Chobanian
- Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Dorothy Levorse
- Discovery and Preclinical Sciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Mengwei Hu
- Discovery and Preclinical Sciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Brande Thomas-Fowlkes
- Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Michael Margulis
- Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Martin Koehler
- Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Adam Weinglass
- Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Jack Gibson
- Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Kevin Houle
- Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Joel Yudkovitz
- Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Caryn Hampton
- Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Lee-Yuh Pai
- Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Koppara Samuel
- Pharmacokinetics Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Timothy Cutarelli
- Discovery Process Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Kathleen Sullivan
- Quantitative Biosciences, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Emma R Parmee
- Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Ian Davies
- Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| | - Alexander Pasternak
- Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States
| |
Collapse
|
6
|
Kharade SV, Kurata H, Bender AM, Blobaum AL, Figueroa EE, Duran A, Kramer M, Days E, Vinson P, Flores D, Satlin LM, Meiler J, Weaver CD, Lindsley CW, Hopkins CR, Denton JS. Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992. Mol Pharmacol 2018; 94:926-937. [PMID: 29895592 DOI: 10.1124/mol.118.112359] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Accepted: 05/30/2018] [Indexed: 12/28/2022] Open
Abstract
The inward rectifier potassium (Kir) channel Kir4.1 (KCNJ10) carries out important physiologic roles in epithelial cells of the kidney, astrocytes in the central nervous system, and stria vascularis of the inner ear. Loss-of-function mutations in KCNJ10 lead to EAST/SeSAME syndrome, which is characterized by epilepsy, ataxia, renal salt wasting, and sensorineural deafness. Although genetic approaches have been indispensable for establishing the importance of Kir4.1 in the normal function of these tissues, the availability of pharmacological tools for acutely manipulating the activity of Kir4.1 in genetically normal animals has been lacking. We therefore carried out a high-throughput screen of 76,575 compounds from the Vanderbilt Institute of Chemical Biology library for small-molecule modulators of Kir4.1. The most potent inhibitor identified was 2-(2-bromo-4-isopropylphenoxy)-N-(2,2,6,6-tetramethylpiperidin-4-yl)acetamide (VU0134992). In whole-cell patch-clamp electrophysiology experiments, VU0134992 inhibits Kir4.1 with an IC50 value of 0.97 µM and is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50 = 9 µM) at -120 mV. In thallium (Tl+) flux assays, VU0134992 is greater than 30-fold selective for Kir4.1 over Kir1.1, Kir2.1, and Kir2.2; is weakly active toward Kir2.3, Kir6.2/SUR1, and Kir7.1; and is equally active toward Kir3.1/3.2, Kir3.1/3.4, and Kir4.2. This potency and selectivity profile is superior to Kir4.1 inhibitors amitriptyline, nortriptyline, and fluoxetine. Medicinal chemistry identified components of VU0134992 that are critical for inhibiting Kir4.1. Patch-clamp electrophysiology, molecular modeling, and site-directed mutagenesis identified pore-lining glutamate 158 and isoleucine 159 as critical residues for block of the channel. VU0134992 displayed a large free unbound fraction (fu) in rat plasma (fu = 0.213). Consistent with the known role of Kir4.1 in renal function, oral dosing of VU0134992 led to a dose-dependent diuresis, natriuresis, and kaliuresis in rats. Thus, VU0134992 represents the first in vivo active tool compound for probing the therapeutic potential of Kir4.1 as a novel diuretic target for the treatment of hypertension.
Collapse
Affiliation(s)
- Sujay V Kharade
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Haruto Kurata
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Aaron M Bender
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Anna L Blobaum
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Eric E Figueroa
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Amanda Duran
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Meghan Kramer
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Emily Days
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Paige Vinson
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Daniel Flores
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Lisa M Satlin
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Jens Meiler
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - C David Weaver
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Craig W Lindsley
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Corey R Hopkins
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| | - Jerod S Denton
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)
| |
Collapse
|